Dose-Escalation Study of SCD-101 in Sickle Cell Disease

Sickle Cell Disease Clinical Trial

Official title:

Part A: Phase IB, Single Site, Dose-Escalation of SCD-101 and Part B: Randomized, Double-Blind, Placebo-Controlled Crossover of SCD-101 in Adults With Homozygous Sickle Cell Disease or S/Beta 0 Thalassemia.

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT02380079
• Other study ID #: INVX-SCD-101-11
• Status: Active, not recruiting
• Phase: Phase 1
• Start date: February 2015
• Est. completion date: December 2023

Study information

• Verified date: March 2023
• Source: Invenux, LLC
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine the safety and clinical effects of SCD-101 when given to adults with sickle cell disease.

Description:

This is single site, dose- escalation study of SCD-101 in participants with homozygous sickle cell disease (S/S) or S/beta 0 Thalassemia. All participants will be monitored for safety, tolerability, and dose-limiting toxicities.

The study is divided into two parts. Part A is an open-label, non-randomized, non-placebo-controlled dose escalation study with a 28-day treatment phase and 14-day follow-up phase with five cohorts . Part B is a randomized, placebo-controlled, confirmatory 2x2 crossover cohort with a 28 day washout between periods, and a 28-day follow-up phase.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 60
• Est. completion date: December 2023
• Est. primary completion date: November 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

1. Male or female, 18-55 years of age

2. Homozygous sickle cell disease or S/beta 0 thalassemia

3. Hemoglobin F =10%

4. Hemoglobin = 6.0 g/dL and = 9.5 g/dL

5. Female participants of child bearing potential and male participants whose partner is a female of child bearing potential must be willing to use approved contraception during the trial and for 3 months following the end of treatment. Only barrier methods or complete abstinence are acceptable for this study. Participants using hormonal contraception (including morning-after-pill) and IUD are excluded unless willing/able to change to an acceptable form of contraception.

6. Ability to adhere to the study visit schedule and other protocol requirements

7. Ability to understand and the willingness to sign an informed consent document

Exclusion Criteria:

1. Red blood cell transfusion within 3 months of enrollment

2. Hydroxyurea treatment within 6 months of enrollment

3. Painful or other acute sickle cell event that required a hospitalization within 4-weeks of enrollment

4. AST and/or ALT >3x upper limit of normal and/or creatinine >2x upper limit of normal or any other significant renal or hepatic impairment

5. Estimated creatinine clearance (CrCl) < 60 mL/min (Cockcroft- Gault formula) at screening.

6. QTc interval of >470 msec at trial entry and participant with congenital long QT syndrome.

7. No other significant sickle cell or non-sickle cell illness that would confound the results of the trial

8. Any condition that, in the view of the investigator, places the participant at risk because of participation in the trial, or may influence the result of the trial or the participant's ability to participate in the trial

9. Participant pregnant or nursing an infant or planning pregnancy during the course of the trial

10. History of allergic reactions attributed to sorghum or compounds of similar chemical or biologic composition (such as Nicosan, Niprisan, Jobelyn or Xickle).

11. Other investigational drug use within 3 months of enrollment

12. PROMIS Fatigue Questionnaire 8a T-score ? 44.3

Related Conditions & MeSH terms

• Anemia, Sickle Cell
• Sickle Cell Disease
• Sickle-Beta Zero Thalassemia
• Thalassemia

Intervention

Drug:
• SCD-101
Administered as gelatin capsules

Locations

Country	Name	City	State
United States	King's County Hospital	Brooklyn	New York

Sponsors (2)

Lead Sponsor	Collaborator
Invenux, LLC	State University of New York - Downstate Medical Center

Country where clinical trial is conducted

United States, 

References & Publications (4)

Iyamu EW, Turner EA, Asakura T. In vitro effects of NIPRISAN (Nix-0699): a naturally occurring, potent antisickling agent. Br J Haematol. 2002 Jul;118(1):337-43. doi: 10.1046/j.1365-2141.2002.03593.x. — View Citation

Iyamu EW, Turner EA, Asakura T. Niprisan (Nix-0699) improves the survival rates of transgenic sickle cell mice under acute severe hypoxic conditions. Br J Haematol. 2003 Sep;122(6):1001-8. doi: 10.1046/j.1365-2141.2003.04536.x. — View Citation

Swift, RA, Nathan, S, Tripathi, P, Chen, Q, Asakura,T (2009, September). Research Preview on Improving Nicosan™/Xickle™: A Phyto-Medicine for the Treatment of Sickle Cell Disease. Paper presented at the meeting of the Sickle Cell Disease Association of America, Orlando, FL.

Wambebe C, Khamofu H, Momoh JA, Ekpeyong M, Audu BS, Njoku OS, Bamgboye EA, Nasipuri RN, Kunle OO, Okogun JI, Enwerem MN, Audam JG, Gamaniel KS, Obodozie OO, Samuel B, Fojule G, Ogunyale O. Double-blind, placebo-controlled, randomised cross-over clinical trial of NIPRISAN in patients with Sickle Cell Disorder. Phytomedicine. 2001 Jul;8(4):252-61. doi: 10.1078/0944-7113-00040. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Part B: Exploratory Outcome Measure the mean change from baseline in sleep interference as measured by the PROMIS sleep interference questionnaire		From the time the participant is accessed at baseline through the final follow-up (18 weeks)
Other	Part B: Exploratory Outcome Measure the mean change from baseline in pain interference as measured by the PROMIS pain interference questionnaire		From the time the participant is accessed at baseline through the final follow-up (18 weeks)
Other	Part B: Exploratory Outcome Measure the mean change from baseline in patient reported daily pain as measured by a Numeric Rating Scale (NRS 0-10)		From the time the participant is accessed at baseline through the final follow-up (18 weeks)
Other	Part B: Exploratory Outcome Measure the mean change from baseline in analgesic usage as measured by patient medication diary		From the time the participant is accessed at baseline through the final follow-up (18 weeks)
Other	Part B: Exploratory Outcome Measure the mean:change from baseline in exercise and sleep activity as measured by wrist actigraphy		From the time the participant is accessed at baseline through the final follow-up (18 weeks)
Other	Part B: Exploratory Outcome Measure the mean:change from baseline in plasma inflammatory cytokines as measured by ELISA		From the time the participant is accessed at baseline through the final follow-up (18 weeks)
Primary	Determine the safety, tolerability, and dose limiting toxicities of escalating doses of SCD-101, assessed by frequency and severity of adverse events (AEs), and changes in vital signs, 12-lead ECGs and laboratory assessments as compared to baseline		From the time the participant is administered the first dose through the final follow-up (18 weeks)
Secondary	Determine the effect of escalating doses of SCD-101 on the mean change in hemoglobin form base line		From the time the participant is accessed at baseline through the final follow-up (18 weeks)
Secondary	Determine the effect of escalating doses of SCD-101 on the mean change in percent reticulocytes from baseline		From the time the participant is accessed at baseline through the final follow-up (18 weeks)
Secondary	Determine the effect of escalating doses of SCD-101 on the mean change from baseline in red blood cell hemolysis as measured by lactate dehydrogenase (LDH) and indirect bilirubin.		From the time the participant is accessed at baseline through the final follow-up (18 weeks)
Secondary	Determine the effect of escalating doses of SCD-101 on the mean change from baseline in fatigue as measured by the PROMIS fatigue questionnaire		From the time the participant is accessed at baseline through the final follow-up (18 weeks)
Secondary	Determine the effect of escalating doses of SCD-101 on the mean change from baseline in the percent of venous circulating sickle red blood cells		From the time the participant is accessed at baseline through the final follow-up (18 weeks)
Secondary	Determine the effect of escalating doses of SCD-101 on the mean change from baseline in functional capacity as measured by the 6-Minute Walk Test		From the time the participant is accessed at baseline through the final follow-up (18 weeks)